Drug intelligence / Profile preview

2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]ethanol

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
01

Overview

This compound is an experimental small molecule belonging to the class of organic compounds known as 2,3-diphenylfurans. It has a molecular formula of C20H17N3O2 and a molecular weight of approximately 331.37 g/mol. The compound has been studied as an inhibitor of serine/threonine-protein kinase Chk1 (checkpoint kinase 1), which plays a key role in cell cycle regulation and DNA damage response pathways. There are no approved indications or clinical trials beyond preclinical/experimental studies for this molecule. Its mechanism involves binding to Chk1 with moderate affinity (IC50 ~20.9 μM), potentially interfering with cell cycle progression and DNA repair processes by inhibiting Chk1 activity[1][3][6].

Other names
2-(5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-ethanol2-(5,6-Diphenylfuro[2,3-d]pyrimidin-4-ylamino)ethanolEthanol, 2-[5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]
02

Targets

CHEK1 (Checkpoint kinase 1)

Beyond the preview

Go deeper on 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]ethanol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]ethanol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call